Device for delivery of an agent to the eye and other sites

• US 20080167600A1
• Filed: 02/06/2006
• Published: 07/10/2008
• Est. Priority Date: 09/26/2005
• Status: Abandoned Application

• Current Assignee: Minu, LLC
• Original Assignee: Minu, LLC
• Inventors: Peyman, Gholam A.
• Application Number:
  US11/348,151
• Publication Number:
  US 20080167600A1
• Time in Patent Office: Days
• US Class Current: 604/20
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators

Abstract

A method and device for delivering an agent, such as an anti-vascular endothelial growth factor (VEGF) agent to ameliorate inflammation, at a site in the body that may be the eye, a joint, the brain, etc. The device located at the body site administers agent using an equilibrium diffusion process.

Claims

1. A device for delivering an agent, the device adapted to have at least a portion positioned within a fluid-filled body part, the device comprising

a proximal portion having a reservoir adapted to contain an agent;

an extension portion coupled to the proximal portion and adapted to be positioned within the body part containing fluid, the extension portion including an interior space for containing the agent and at least one aperture in an outer surface of the extension portion and in fluid communication with the interior space; and

an adjustable barrier juxtaposed between the reservoir of the proximal portion and the interior space of the extension portion, the barrier having at least one aperture for permitting fluid communication between the reservoir and the interior space, wherein the aperture is adapted to control the rate at which the agent enters the extension portion and thereafter equilibrates with the fluid in the body part.

2. The device of claim 1 wherein the proximal and extension portions of the device further comprise a relatively more rigid outer shell formed from a substantially biodegradable polymer for providing a structural aspect to the device;

and

a relatively less rigid inner bladder formed from a substantially non-biodegradable polymer for permitting diffusion of the agent into the fluid, the outer shell initially substantially encapsulating the inner bladder.

3. The device of claim 1 wherein the proximal and extensions portions of the device further comprise

a bladder formed from a substantially non-biodegradable polymer for permitting diffusion of the agent, the bladder expandable between a first position and a second position;

and

a sleeve formed from a substantially non-biodegradable polymer for providing a structural aspect to the device, the sleeve substantially encapsulating the extension portion when the bladder is in the first position and at least a portion of the bladder extending beyond an end of the sleeve when in the second position.

4. The device of claim 1 further comprising an electrode associated with the device for iontophoresis administration of the agent.

5. An ocular device for delivering an agent the device comprising

a proximal portion having a reservoir adapted to contain an agent;

an extension portion coupled to the proximal portion and adapted to be positioned within a vitreous cavity containing vitreous fluid, the extension portion including an interior space for containing the agent and at least one aperture in an outer surface of the extension portion and in fluid communication with the interior space; and

an adjustable barrier juxtaposed between the reservoir of the proximal portion and the interior space of the extension portion, the barrier having at least one aperture for permitting fluid communication between the reservoir and the interior space, wherein the aperture is adapted to control the rate at which the agent enters the extension portion and thereafter equilibrates with vitreous fluid in the vitreous cavity.

6. The ocular device of claim 5 wherein the proximal and extension portions of the device further comprise

a relatively more rigid outer shell formed from a substantially biodegradable polymer for providing a structural aspect to the device;

and

a relatively less rigid inner bladder formed from a substantially non-biodegradable polymer for permitting diffusion of the agent into the fluid, the outer shell initially substantially encapsulating the inner bladder.

7. The ocular device of claim 5 wherein the proximal and extensions portions of the device further comprise

a bladder formed from a substantially non-biodegradable polymer for permitting diffusion of the agent, the bladder expandable between a first position and a second position;

and

a sleeve formed from a substantially non-biodegradable polymer for providing a structural aspect to the device, the sleeve substantially encapsulating the extension portion when the bladder is in the first position and at least a portion of the bladder extending beyond an end of the sleeve when in the second position.

8. The ocular device of claim 5 further comprising an electrode associated with the device for iontophoresis administration of the agent.

9. A method of ameliorating an ocular inflammatory process in a patient comprising providing to an eye of the patient a therapeutic concentration of at least one anti-vascular endothelial growth factor (VEGF) agent as the anti-inflammatory agent, the agent provided with a device to achieve a diffusion concentration of the anti-VEGF agent in the vitreous cavity at a concentration sufficient to ameliorate ocular inflammation.

10. The method of claim 9 wherein that anti-VEGF agent is bevacizumab administered at a concentration of up to about 5 mg/0.1 ml.

11. The method of claim 9 wherein the anti-VEGF agent is selected from at least one of bevacizumab, ranibizumab, pegaptanib, sunitinib maleate, TNP470, integrin av antagonists, 2-methoxyestradiol, paclitaxel, or P38 mitogen activated protein kinase inhibitors.